🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

29 recruiting trials

for Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

A Study to Observe the Safety of VYLOY (Zolbetuximab) in People in South Korea With Gastric or Gastroesophageal Junction Cancer. NCT06902545n/a15 sites📍 Goyang-si📍 Suwon📍 Suwon Astellas Pharma Korea, Inc. · Tests: zolbetuximab A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma NCT07043400Phase 395 sites📍 Chandler📍 Los Alamitos📍 Colorado Springs BeOne Medicines · Tests: Subcutaneous Tislelizumab, Intravenous Tislelizumab, Cisplatin, Leucovorin, 5-fluorouracil (5-FU) First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2) NCT06730373Phase 220 sites📍 Zhengzhou📍 Binzhou📍 Dongying Qilu Hospital of Shandong University · Tests: Disitamab Vedotin, Sintilimab, S-1, Trastuzumab, Oxaliplatin mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma NCT05677490Phase 3798 sites📍 Birmingham📍 Anchorage📍 Anchorage Alliance for Clinical Trials in Oncology · Tests: Fluorouracil, Leucovorin Calcium, Oxaliplatin, Irinotecan, Nivolumab A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer NCT06901531Phase 3252 sites📍 Birmingham📍 Bakersfield📍 Cerritos Astellas Pharma Global Development, Inc. · Tests: zolbetuximab, Pembrolizumab, Capecitabine, Oxaliplatin, Folinic acid (leucovorin or local equivalent) A Phase Ib/II Study of ATG-022 Plus Pembrolizumab With/Without Chemotherapy in Participants With Claudin (CLDN) 18.2-positive, HER2-negative, Unresectable or Metastatic Gastric or Gastroesophageal Junction AdenocarcinomaUnresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma NCT07327229Phase 1, Phase 230 sites📍 Hefei📍 Hefei📍 Beijing Antengene Biologics Limited · Tests: ATG-022, pembrolizumab/KEYTRUDA®, CAPOX SHR-A1811 for Subjects With Her2-positive Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on or After First-line Anti-HER2 Therapy-containing Regimen NCT06123494Phase 31 site📍 Shanghai Jiangsu HengRui Medicine Co., Ltd. · Tests: SHR-A1811, Ramucirumab / Paclitaxel/ Docetaxel/ Irinotecan Chemoradiotherapy and SHR-1701 in Patients With Unresectable Gastric Cancer NCT07689851Phase 23 sites📍 Shenzhen📍 Taiyuan📍 Beijing Cancer Institute and Hospital, Chinese Academy of Medical S… · Tests: COPOX, Radiotherapy, SHR-1701 QLS31905 in Combination With CAPOX Versus Sintilimab in Combination With CAPOX as First-line Treatment in Patients With GC/GEJ NCT07716449Phase 31 site📍 Beijing Qilu Pharmaceutical Co., Ltd. · Tests: QLS31905, Sintilimab, Oxaliplatin, Capecitabine Study of IBI363 in Patients with Advanced First-line Gastric Cancer NCT06610799Phase 11 site📍 Hangzhou Xiangdong Cheng · Tests: IBI363 Phase 3 Study of Cadonilimab Combined With Chemotherapy vs Chemotherapy in Combination With or Without Nivolumab for the 1L Treatment of Participants With HER2-negative, Previously Untreated, Unresectable or Metastatic Gastric/GEJ Adenocarcinoma NCT07700979Phase 325 sites📍 Phoenix📍 Los Angeles📍 Denver Akeso · Tests: Cadonilimab, CAPOX regimen, Nivolumab, Placebo A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors NCT07488676Phase 1, Phase 221 sites📍 Birmingham📍 Los Angeles📍 Miami Astellas Pharma Global Development, Inc. · Tests: ASP546C Tislelizumab Plus FOLFOX Versus POF in the Treatment of Locally Advanced: a Multicenter, Open-label, Randomized Phase III Studyunresectable or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma NCT06793917Phase 31 site📍 Fuzhou Fujian Cancer Hospital · Tests: Tislelizumab, Oxaliplatin injection, Levo-Leucovorin, 5-fluorouracil, Paclitaxel A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer NCT05365581Phase 146 sites📍 Orange📍 Santa Monica📍 Chicago Astellas Pharma Global Development, Inc. · Tests: ASP2138, Pembrolizumab, Oxaliplatin, Leucovorin, Fluorouracil A Study of ASP2138 Together With Chemotherapy and Pembrolizumab in Adults With Gastric Cancer NCT07673887Phase 38 sites📍 Saint Louis Park📍 Guangzhou📍 Guangzhou Astellas Pharma Global Development, Inc. · Tests: ASP2138, Pembrolizumab, Oxaliplatin, Capecitabine, Folinic acid Ramucirumab and Trifluridine/Tipiracil or Paclitaxel for the Treatment of Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer NCT04660760Phase 215 sites📍 Birmingham📍 Scottsdale📍 Tucson Academic and Community Cancer Research United · Tests: Paclitaxel, Quality-of-Life Assessment, Ramucirumab, Trifluridine and Tipiracil Hydrochloride Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial NCT06203600Phase 2, Phase 3378 sites📍 Little Rock📍 Little Rock📍 Anaheim National Cancer Institute (NCI) · Tests: Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Nivolumab, Paclitaxel Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors NCT05269381Phase 1, Phase 21 site📍 Jacksonville Mayo Clinic · Tests: Cyclophosphamide, Neoantigen Peptide Vaccine, Pembrolizumab, Sargramostim, Biospecimen Collection Safety and Efficacy of SHR2554 Combined With Other Antitumor Therapies in Gastric or Gastro-oesophageal Junction Adenocarcinoma NCT07102901Phase 22 sites📍 Harbin📍 Zhengzhou Jiangsu HengRui Medicine Co., Ltd. · Tests: SHR2554 Tablets, SHR-A1811 Injection, SHR-A1904 Injection, SHR-1701 Injection Phase II Trial of Iparomlimab/Tuvonralimab (QL1706) + XELOX in HER2-Negative, Low PD-L1 G/GEJ Adenocarcinoma NCT06932068Phase 229 sites📍 Zhengzhou📍 Binzhou📍 Dezhou Qilu Hospital of Shandong University · Tests: Iparomlimab and Tuvonralimab (QL1706), Oxallplation, Capectitabine Tablets M108 Plus CAPOX Versus Placebo Plus CAPOX as First-line Treatment for Claudin (CLDN) 18.2-Positive, HER2-Negative, PD-L1 CPS<5, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma. NCT06177041Phase 31 site📍 Beijing FutureGen Biopharmaceutical (Beijing) Co., Ltd · Tests: M108 monoclonal antibody, Placebo, Oxaliplatin, Capecitabine A Phase III Study of SHR-A1811 in Combination With Chemotherapy and Adebrelimab in Previously Untreated Patients With Gastric or Gastroesophageal Junction Adenocarcinoma NCT07118527Phase 32 sites📍 Shenyang📍 Shanghai Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Tests: SHR-A1811 + Adebrelimab Injection + Capecitabine Tablets or Fluorouracil Injection, Trastuzumab + Pembrolizumab + CAPOX… KN026 in Combination With Chemotherapy in HER2 Positive Gastric Cancer Subjects Who Have Failed First-line Therapy NCT05427383Phase 2, Phase 31 site📍 Beijing Shanghai JMT-Bio Inc. · Tests: KN026/Placbo Injection, Paclitaxel Injection, Docetaxel Injection, Irinotecan Injection Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma. NCT07385703Phase 3106 sites📍 Hefei📍 Hefei📍 Hefei Shanghai Chia Tai Tianqing Pharmaceutical Technology Develo… · Tests: LM-302 Injection, Tislelizumab, Oxaliplatin Injection, Capecitabine Tablets Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma NCT05702229Phase 244 sites📍 Los Angeles📍 Los Angeles📍 Baton Rouge AstraZeneca · Tests: Rilvegostomig, Volrustomig, FOLFOX, XELOX, AZD0901 The Efficacy and Safety of LM-302 in Combination With Candonilimab and Capecitabine for First-Line Treatment in Patients With Unresectable Advanced, Recurrent, or Metastatic CLDN18.2-Positive Gastric or Gastroesophageal Junction Adenocarcinoma NCT06587425Phase 21 site📍 Shanghai Shanghai Zhongshan Hospital · Tests: LM-302+Candonilimab+Capecitabine Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients With Stomach or Other Solid Tumors NCT06364410Phase 11 site📍 Houston National Cancer Institute (NCI) · Tests: Azenosertib, Biopsy Procedure, Biospecimen Collection, Computed Tomography, Echocardiography Test Study of Denikitug (GS-1811) Given Alone or With Nivolumab or Chemotherapy in Adults With Metastatic Gastric, Gastroesophageal Junction (GEJ), and Esophageal Adenocarcinomas NCT07546812Phase 215 sites📍 Boston📍 Boston📍 Albany Gilead Sciences · Tests: Denikitug, Nivolumab, Ramucirumab, Paclitaxel IBI343 Combined With Sintilimab Plus Chemotherapy in Gastric Cancer NCT07025889Phase 1, Phase 21 site📍 Shanghai Ruijin Hospital · Tests: IBI343, Sintilimab, Oxaliplatin, S-1
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy